Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Filter By:

Search by Keyword (disease, investigator, treatment name):

Study of Avelumab-M3814 Combinations

Multiple Cancer Types

The main purpose of the study is to evaluate a safe, tolerable recommended Phase II dose (RP2D) and / or the maximum tolerated dose (MTD) of M3814 when given in combination with avelumab with and without radiotherapy in participants with selected advanced solid tumors.

Disease Sites: Miscellaneous, Phase I

Phase: I

Investigator: Iams, Wade

NCTID: NCT03724890

Protocol No: VICCPHI18160

Learn More